Skip to search formSkip to main contentSkip to account menu

edoxaban

Known as: Ethanediamide, n1-(5-chloro-2-pyridinyl)-n2-((1s,2r,4s)-4- ((dimethylamino)carbonyl)- 2-(((4,5,6,7-tetrahydro-5-methylthiazolo(5,4-c)pyridin-2-yl)carbonyl)amino)cyclohexyl)-, N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl]oxamide, N-(5-chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide 
An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Background Low‐molecular‐weight heparin is the standard treatment for cancer‐associated venous thromboembolism. The role of… 
Highly Cited
2016
Highly Cited
2015
Highly Cited
2015
Background— The oral factor Xa inhibitor edoxaban has demonstrated safety and efficacy in stroke prevention in patients with… 
Highly Cited
2014
Highly Cited
2014
Among 80 healthy persons who had received a single dose of edoxaban, the whole-blood clotting time was reduced significantly more… 
Review
2014
Review
2014
New direct oral anticoagulants (NOACs) constitute a novel treatment option for acute venous thromboembolism (VTE), with practical… 
Highly Cited
2013
Highly Cited
2013
BACKGROUND Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of… 
Highly Cited
2013
Highly Cited
2013
BACKGROUND Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous… 
Highly Cited
2010
Highly Cited
2010
This is a clinical safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) study of a single ascending dose (SAD… 
Highly Cited
2010
Highly Cited
2010
The primary objective of this study was to compare the safety of four fixed-dose regimens of edoxaban with warfarin in patients…